GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

A Study Assessing the Safety, Efficacy, and Impact of GlaxoSmithKline Biologicals' RTS, S/AS01E Malaria Vaccine in Young Children Across Sub-Saharan Africa

Recruiting

Conditions: Malaria
Malaria Vaccines

Interventions: Procedure: Whole blood sample

First Posted Date: 2019-02-27

Last Posted Date: 2025-02-18

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 78000

Registration Number: NCT03855995

Locations: 🇲🇼
GSK Investigational Site, Mangochi, Malawi

Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: belantamab mafodotin
Drug: Pembrolizumab

First Posted Date: 2019-02-21

Last Posted Date: 2024-04-09

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 41

Registration Number: NCT03848845

Locations: 🇪🇸
GSK Investigational Site, Salamanca, Spain

A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Neoplasms

Interventions: Drug: GSK3745417
Drug: Dostarlimab

First Posted Date: 2019-02-18

Last Posted Date: 2024-08-09

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 97

Registration Number: NCT03843359

Locations: 🇪🇸
GSK Investigational Site, Madrid, Spain

An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Belantamab mafodotin
Drug: Bortezomib
Drug: Dexamethasone
Drug: Pomalidomide

First Posted Date: 2019-02-04

Last Posted Date: 2025-04-10

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 15

Registration Number: NCT03828292

Locations: 🇯🇵
GSK Investigational Site, Tokyo, Japan

A Study to Evaluate the Efficacy, Immunogenicity and Safety in a Sporozoite Challenge Model of a Fractional Booster Dose of GSK Biologicals' Candidate Malaria Vaccine Administered to Previously Vaccinated Healthy Malaria-naïve Adults

Phase 2

Completed

Conditions: Malaria

Interventions: Biological: RTS,S/AS01E (SB257049)

First Posted Date: 2019-01-31

Last Posted Date: 2020-08-14

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 61

Registration Number: NCT03824236

Locations: 🇺🇸
GSK Investigational Site, Silver Spring, Maryland, United States

A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults

Phase 1

Completed

Conditions: Respiratory Syncytial Virus Infections

Interventions: Drug: Placebo (Saline solution)
Biological: RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01E
Biological: RSV Vaccine (GSK3844766A) unadjuvanted low dose
Biological: RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01B
Biological: RSV Vaccine (GSK3844766A) unadjuvanted high dose
Biological: RSV Vaccine (GSK3844766A) unadjuvanted medium dose
Biological: RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01B
Biological: RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01E
Biological: RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01B
Biological: RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01E

First Posted Date: 2019-01-24

Last Posted Date: 2022-08-05

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1053

Registration Number: NCT03814590

Locations: 🇧🇪
GSK Investigational Site, Wilrijk, Belgium

Dental Plaque Removal Ability of Prototype Power Toothbrush Versus a Manual Toothbrush in Healthy Participants

Phase 2

Completed

Conditions: Dental Plaque

Interventions: Device: Prototype PTB (Gum line mode)
Device: Reference MTB
Device: Reference PTB
Device: Prototype PTB (Combined mode)

First Posted Date: 2019-01-18

Last Posted Date: 2020-09-16

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 40

Registration Number: NCT03809910

Locations: 🇨🇦
GSK Investigational Site, Mississauga, Canada

To Evaluate Oral Health and Quality of Life Associated With Use of a Denture Adhesive

Phase 3

Completed

Conditions: Denture Retention

Interventions: Drug: Experimental Denture Adhesive

First Posted Date: 2019-01-17

Last Posted Date: 2021-09-05

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 119

Registration Number: NCT03807700

Locations: 🇨🇦
GSK Investigational Site, Mississauga, Canada

To Evaluate the Effect of Moisturizing Creams on Skin Barrier Function

Not Applicable

Completed

Conditions: Dry Skin
Skin Care

Interventions: Drug: Developmental moisturizing cream 1
Drug: Developmental moisturizing cream 2
Other: Standard cleanser soap

First Posted Date: 2019-01-15

Last Posted Date: 2020-06-04

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 158

Registration Number: NCT03804710

Locations: 🇩🇪
GSK Investigational Site, Schenefeld, Schleswig-Holstein, Germany

A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal Vaccine

Phase 1

Completed

Conditions: Pneumococcal Disease
Pneumonia, Bacterial
Healthy Volunteers

Interventions: Biological: ASP3772
Biological: PCV13
Biological: PPSV23

First Posted Date: 2019-01-14

Last Posted Date: 2023-12-21

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 630

Registration Number: NCT03803202

Locations: 🇺🇸
Benchmark Research, San Angelo, Texas, United States
🇺🇸
Artemis Institute, San Marcos, California, United States
🇺🇸
Research Centers of America, Hollywood, Florida, United States

and more 19 locations

Home Terms & Conditions Privacy Policy